A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...

Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

The drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...